These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of epoxide hydrolase by anticonvulsants and risk of teratogenicity. Kerr BM; Levy RH Lancet; 1989 Mar; 1(8638):610-1. PubMed ID: 2564126 [No Abstract] [Full Text] [Related]
23. Purification of microsomal epoxide hydrolase from liver of rhesus monkey: partial separation of cis- and trans-stilbene oxide hydrolase. Moody DE; Hammock BD Arch Biochem Biophys; 1987 Oct; 258(1):156-66. PubMed ID: 3310896 [TBL] [Abstract][Full Text] [Related]
24. Rat cytosolic epoxide hydrolase. Oesch F; Schladt L; Hartmann R; Timms C; Wörner W Adv Exp Med Biol; 1986; 197():195-201. PubMed ID: 3766258 [TBL] [Abstract][Full Text] [Related]
25. Interaction of valproic acid and some analogues with microsomal epoxide hydrolase. Robbins DK; Wedlund PJ; Elsberg S; Oesch F; Thomas H Biochem Pharmacol; 1992 Feb; 43(4):775-83. PubMed ID: 1540232 [TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of valpromide. Bialer M Clin Pharmacokinet; 1991 Feb; 20(2):114-22. PubMed ID: 2029804 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the sex and subcellular distributions, catalytic and immunochemical reactivities of hepatic epoxide hydrolases in seven mammalian species. Meijer J; Lundqvist G; DePierre JW Eur J Biochem; 1987 Sep; 167(2):269-79. PubMed ID: 3113952 [TBL] [Abstract][Full Text] [Related]
28. Epoxide hydrolase in human fetal liver. Pacifici GM; Rane A Pharmacology; 1983; 26(5):241-8. PubMed ID: 6682981 [TBL] [Abstract][Full Text] [Related]
29. Can we develop improved derivatives of valproic acid? Bialer M; Haj-Yehia A; Badir K; Hadad S Pharm World Sci; 1994 Feb; 16(1):2-6. PubMed ID: 8156045 [TBL] [Abstract][Full Text] [Related]
34. Distribution and nature of epoxide hydrolase activity in subcellular organelles of mouse liver. Kaur S; Gill SS Biochem Pharmacol; 1986 Apr; 35(8):1299-308. PubMed ID: 3083822 [TBL] [Abstract][Full Text] [Related]
35. Distribution and inducibility of cytosolic epoxide hydrolase in male Sprague-Dawley rats. Schladt L; Wörner W; Setiabudi F; Oesch F Biochem Pharmacol; 1986 Oct; 35(19):3309-16. PubMed ID: 3768023 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of epoxide metabolism by alpha,beta-epoxyketones and isosteric analogs. Prestwich GD; Kuo JW; Park SK; Loury DN; Hammock BD Arch Biochem Biophys; 1985 Oct; 242(1):11-5. PubMed ID: 4051497 [TBL] [Abstract][Full Text] [Related]
37. Saccharomyces cerevisiae: an alternative source for human microsomal liver enzymes and its use in drug interaction studies. Eugster HP; Sengstag C Toxicology; 1993 Oct; 82(1-3):61-73. PubMed ID: 8236282 [TBL] [Abstract][Full Text] [Related]
38. Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. Rosa M; Bonnaillie P; Chanteux H Xenobiotica; 2016 Dec; 46(12):1076-1084. PubMed ID: 26936324 [TBL] [Abstract][Full Text] [Related]
39. Hepatic epoxide hydrolase activities and their induction by clofibrate and diethylhexylphthalate in various strains of mice. Gill SS; Kaur S Biochem Pharmacol; 1987 Dec; 36(24):4221-7. PubMed ID: 3318844 [TBL] [Abstract][Full Text] [Related]